Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Decoy Therapeutics Inc.SLRX · Entity 937 | Controller | September 10, 2019 | September 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Decoy Therapeutics Inc.
Report date September 10, 2019 · Filed September 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2029-09-10 | Direct | 10,000 |
Reported balance
After 2019-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-09-10 · Grant · Acquired 10,000 · Balance 10,000 F1: The grant has a 4-year vesting schedule with 25% vesting on September 30, 2020 and 1/12th of the balance vesting on the last day of each calendar quarter thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant has a 4-year vesting schedule with 25% vesting on September 30, 2020 and 1/12th of the balance vesting on the last day of each calendar quarter thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2019 Filed Sep 13, 2019 01:58 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001615219-19-000033 · wf-form4_156833991916830.xml · derivative · entry 1 Chuang Pao-Yu · CIK 0001782864 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-09-10 F1 · derivative.exercise_date: The grant has a 4-year vesting schedule with 25% vesting on September 30, 2020 and 1/12th of the balance vesting on the last day of each calendar quarter thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.